Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

NCT06816771 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Rhabdomyosarcoma, Recurrent, Refractory

Interventions

DRUG: pazopanib
DRUG: TGI chemotherapy
DRUG: CIV chemotherapy

Sponsor

Shandong Cancer Hospital and Institute